Human Anti-CA19-9 Recombinant Antibody (clone 5B1) (CAT#: HPAB-0038-WJ)
This product is a human monoclonal IgG1 antibody targeting sialyl-Lewis(a) (sLea), an epitope present on the CA19-9 cancer antigen. On the basis of the potential of sLea as a target for immune attack and their affinity, specificity, and effector functions, this antibody has clinical utility in the treatment of cancer.
Specific Inquiry
IHC
Figure 1 Histology (A–C, Left), autoradiography (A–C, Center), and fluorescence microscopy (A–C, Right) of resected tumor tissue from mice injected with ⁸⁹Zr-ˢˢdual-5B1.
(A) A BxPC3 xenograft, (B) metastatic foci from a mouse with a Suit-2 orthotopic xenograft, and (C) the primary tumor with surrounding healthy pancreas tissue from the same mouse are shown, confirming colocalization of the tracer with CA19.9 expression.
Houghton, J. L., Zeglis, B. M., Abdel-Atti, D., Aggeler, R., Sawada, R., Agnew, B. J., ... & Lewis, J. S. (2015). Site-specifically labeled CA19. 9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. Proceedings of the National Academy of Sciences, 112(52), 15850-15855.
IRMA
Figure 2 Histology (A–C, Left), autoradiography (A–C, Center), and fluorescence microscopy (A–C, Right) of resected tumor tissue from mice injected with ⁸⁹Zr-ˢˢdual-5B1.
(A) A BxPC3 xenograft, (B) metastatic foci from a mouse with a Suit-2 orthotopic xenograft, and (C) the primary tumor with surrounding healthy pancreas tissue from the same mouse are shown, confirming colocalization of the tracer with CA19.9 expression.
Houghton, J. L., Zeglis, B. M., Abdel-Atti, D., Aggeler, R., Sawada, R., Agnew, B. J., ... & Lewis, J. S. (2015). Site-specifically labeled CA19. 9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. Proceedings of the National Academy of Sciences, 112(52), 15850-15855.
IF
Figure 3 Histology (A–C, Left), autoradiography (A–C, Center), and fluorescence microscopy (A–C, Right) of resected tumor tissue from mice injected with ⁸⁹Zr-ˢˢdual-5B1.
(A) A BxPC3 xenograft, (B) metastatic foci from a mouse with a Suit-2 orthotopic xenograft, and (C) the primary tumor with surrounding healthy pancreas tissue from the same mouse are shown, confirming colocalization of the tracer with CA19.9 expression.
Houghton, J. L., Zeglis, B. M., Abdel-Atti, D., Aggeler, R., Sawada, R., Agnew, B. J., ... & Lewis, J. S. (2015). Site-specifically labeled CA19. 9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. Proceedings of the National Academy of Sciences, 112(52), 15850-15855.
Cyt
Figure 4 ADCC activity of r5B1 antibodies.
(A) r5B1 mediated ADCC with human PBMC against DMS-79 cells. PBMC were tested at E:T ratios from 100:1 to 12.5:1 with DMS-79 tumor cells in presence or absence of 2 μg/ml r5B1.
Sawada, R., Sun, S. M., Wu, X., Hong, F., Ragupathi, G., Livingston, P. O., & Scholz, W. W. (2011). Human monoclonal antibodies to sialyl-Lewisa (CA19. 9) with potent CDC, ADCC, and antitumor activity. Clinical Cancer Research, 17(5), 1024-1032.
FC
Figure 5 Binding of human anti-sLeᵃ antibodies to tumor cells analyzed by flow cytometry.
Staining of Colo205-luc cells with 1-2 μg/ml of r5B1 or 7E3 plus IgG or IgM-specific secondary antibody as described in Materials and Methods.
Sawada, R., Sun, S. M., Wu, X., Hong, F., Ragupathi, G., Livingston, P. O., & Scholz, W. W. (2011). Human monoclonal antibodies to sialyl-Lewisa (CA19. 9) with potent CDC, ADCC, and antitumor activity. Clinical Cancer Research, 17(5), 1024-1032.
ELISA
Figure 6 Identification of anti-sLeᵃ monoclonal antibody producing hybridomas derived from vaccinated patient PBMC.
Binding of antibodies to sLeᵃ presented as univalent (mono-) sLeᵃ, multivalent (poly-) sLeᵃ, or sLeᵃ-HSA form measured by ELISA as described in Material and Methods. NAV: Neutral Avidin.
Sawada, R., Sun, S. M., Wu, X., Hong, F., Ragupathi, G., Livingston, P. O., & Scholz, W. W. (2011). Human monoclonal antibodies to sialyl-Lewisa (CA19. 9) with potent CDC, ADCC, and antitumor activity. Clinical Cancer Research, 17(5), 1024-1032.
Specifications
- Host Species
- Human
- Type
- Human IgG1
- Specificity
- Human sLea of CA19-9
- Species Reactivity
- Human
- Clone
- 5B1
- Applications
- ELISA, IHC, IRMA, IF, Cyt, FC
- Related Disease
- Colon cancer, Pancreatic adenocarcinoma
Product Property
- Purity
- >95% as determined by SDS-PAGE and HPLC analysis
- Concentration
- Please refer to the vial label for the specific concentration.
- Buffer
- PBS
- Preservative
- No preservatives
- Storage
- Centrifuge briefly prior to opening vial. Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Applications
- Application Notes
- The CA19-9 antibody has been reported in applications of Enzyme-linked Immunosorbent Assay, Immunohistochemistry, Immunoradiometric Assay, Immunofluorescence, Cytotoxicity, Flow Cytometry.
For FC: sLeᵃ positive or negative tumor cell lines (0.5×10⁶ cells per condition) were washed in PBS/2% FBS (PBSF). Test or control human mAb was then added (1-2μg/ml in complete medium) and incubated on ice for 30 minutes. After washing in PBSF, the cells were incubated with Alexa-488 anti-human IgG (Fcγ) or anti-human IgM (μ) for 30 minutes on ice. Cells were washed twice in PBSF and analyzed by flow cytometry using the Guava Personal Cell Analysis-96 (PCA-96) System. Colo205-luc cells were incubated with 2 μg/ml primary antibody followed by staining with secondary antibodies, and analyzed on a Becton Dickinson FC Advantage IV instrument using FlowJo 7.2.4 software.
For ELISA: For the sLeᵃ ELISA, plates were coated either with 1 μg/ml of sLeᵃ-HSA conjugate, monovalent biotinylated-sLeᵃ, or with polyvalent biotinylated sLeᵃ-PAA captured on Neutravidin coated plates. Uncoated wells (PBS) and human serum albumin (HSA) coated wells were used as controls. Bound antibodies were initially detected with HRP-labeled goat anti-human IgA+G+M and positive wells were subsequently probed with IgG-Fc or IgM specific secondary antibodies to determine isotypes.
Target
- Alternative Names
- CA19-9; Human CA19-9
Product Notes
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Downloads
Download resources about recombinant antibody development and antibody engineering to boost your research.
See other products for "Clone 5B1"
See other products for "CA19-9"
Recombinant Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| MOB-0267MZ | Mouse Anti-CA19-9 Recombinant Antibody (clone 1117-OS-20-10) | IHC | Mouse IgG1 |
| MOB-318YJL | Mouse Anti-CA19-9 Recombinant Antibody (clone 116-NS-19-9) | IHC-P, ICC, IF, FC | Mouse IgG1, κ |
| VS1-YJ20 | Mouse Anti-CA19-9 Recombinant Antibody (clone 121SLE) | FC, ELISA, IHC-P, IHC-fr, WB | Mouse IgM |
| VS3-CJ109 | Mouse Anti-CA19-9 Recombinant Antibody (VS3-CJ109) | IHC, IF | Mouse IgG |
scFv Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0038-WJ-S(P) | Human Anti-CA19-9 Recombinant Antibody (clone 5B1); scFv Fragment | ELISA | Human scFv |
Fab Fragment Antibody
| CAT | Product Name | Application | Type |
|---|---|---|---|
| HPAB-0038-WJ-F(E) | Human Anti-CA19-9 Recombinant Antibody (clone 5B1); Fab Fragment | ELISA | Human Fab |
Customer Reviews and Q&As
There are currently no Customer reviews or questions for HPAB-0038-WJ. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Send Inquiry
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.